Fibrinogen residue γAla341 is necessary for calcium binding and ‘A-a’ interactions

Summary

The fibrinogen γ-module has several important sites relating to fibri-nogen function, which include the high affinity calcium binding site, hole ‘a’ that binds with knob ‘A’, and the D:D interface. Residue γAla341, which is located in the vicinity of these sites, is altered in three variant fibrinogens: fibrinogen Seoul (γAla341Asp), Tolaga Bay (γAla341Val), and Lyon III (γAla341Thr). In order to investigate the impaired polymerisation of fibrinogens γAla341Asp and γAla341Val to understand the role of γAla341 in fibrin polymerisation and fibrinogen synthesis, we have expressed γAla341Asp and γAla341Val in Chinese hamster ovary (CHO) cells, purified these fibrinogens from the culture media and performed biochemical tests to elucidate their function. Expression in CHO cells was similar for these variants. For both variants the kinetics of thrombin-catalysed FpA release was not different from normal fibrinogen, while FpB release was slower than that of normal. Thrombin-catalysed polymerisation of both variants was dependent on the calcium concentration. At physiologic calcium (1 mM) the variants showed impaired polymerisation with a longer lag period and a slower V_max than normal fibrinogen. Scanning electron micrographs showed the clots were less organised than normal, having thicker and more twisted fibers, and larger pores. Analysis by SDS-PAGE showed that factor XIIIa-catalysed γ and α chain cross-linking was delayed, and plas-min-catalysed lysis was not reduced by the presence of 5 mM calcium or 5 mM GPRP (Gly-Pro-Arg-Pro). Our data indicate that fibrinogen residue γAla341 is important for the proper conformation of the γ-module, maintaining calcium-binding site and ‘A-a’ interactions.

Keywords

Dysfibrinogenemia - γAla341 - γ-module - calcium binding - GPRP binding - ‘A-a’ interaction

• References

• 1 Doolittle RF. Fibrinogen and fibrin. Annu Rev Biochem 1984; 53: 195-229.
• 2 Tennent GA, Brennan SO, Stangou AJ. et al. Human plasma fibrinogen is synthesized in the liver. Blood 2007; 109: 1971-1974.
• 3 Mosesson MW. The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 1992; 29: 177-188.
• 4 Medved L, Weisel JW. Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost 2009; 07: 355-359.
• 5 Lord ST. Fibrinogen and fibrin: scaffold proteins in hemostasis. Curr Opin Hema-tol 2007; 14: 236-241.
• 6 Cote HC, Lord ST, Pratt KP. gamma-Chain dysfibrinogenemias: molecular structure-function relationships of naturally occurring mutations in the gamma chain of human fibrinogen. Blood 1998; 92: 2195-2212.
• 7 Everse SJ, Spraggon G, Doolittle RF. A three-dimensional consideration of variant human fibrinogens. Thromb Haemost 1998; 80: 1-9.
• 8 Pratt KP, Cote HC, Chung DW. et al. The primary fibrin polymerization pocket: three-dimensional structure of a 30-kDa C-terminal gamma chain fragment complexed with the peptide Gly-Pro-Arg-Pro. Proc Natl Acad Sci USA 1997; 94: 7176-7181.
• 9 Shimizu A, Nagel GM, Doolittle RF. Photoaffinity labeling of the primary fibrin polymerization site: isolation and characterization of a labeled cyanogen bromide fragment corresponding to gamma-chain residues 337-379. Proc Natl Acad Sci USA 1992; 89: 2888-2892.
• 10 Song KS, Park NJ, Choi JR. et al. Fibrinogen Seoul (FGG Ala341Asp): a novel mutation associated with hypodysfibrinogenemia. Clin Appl Thromb Hemost 2006; 12: 338-343.
• 11 Davis RL, Brennan SO. Fibrinogen Tolaga Bay: a novel gammaAla341Val mutation causing hypofibrinogenaemia. Thromb Haemost 2007; 98: 1136-1138.
• 12 Hanss M, Chevreaud C, French P. et al. Clinical and biological features of 3 cases of hypofibrinogenemia associated with three different mutations (gamma Ala341Thr, Bbeta Tyr326Cys and Aalpha Asp496Asn). Thromb Haemost 2007; 98: 689-691.
• 13 Hogan KA, Lord ST, Okumura N. et al. A functional assay suggests that hetero-dimers exist in two C-terminal gamma-chain dysfibrinogens: Matsumoto I and Vlissingen/Frankfurt IV. Thromb Haemost 2000; 83: 592-597.
• 14 Okumura N, Gorkun OV, Lord ST. Severely impaired polymerization of recom-binant fibrinogen gamma-364 Asp --> His, the substitution discovered in a heterozygous individual. J Biol Chem 1997; 272: 29596-29601.
• 15 Gorkun OV, Veklich YI, Weisel JW. et al. The conversion of fibrinogen to fibrin: recombinant fibrinogen typifies plasma fibrinogen. Blood 1997; 89: 4407-4414.
• 16 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
• 17 Corley RB. A guide to methods in the biomedical sciences / Ronald B. Corley. Springer; New York: 2004
• 18 Mullin JL, Gorkun OV, Binnie CG. et al. Recombinant fibrinogen studies reveal that thrombin specificity dictates order of fibrinopeptide release. J Biol Chem 2000; 275: 25239-25246.
• 19 Park R, Doh HJ, An SS. et al. A novel fibrinogen variant (fibrinogen Seoul II; Aal-phaGln328Pro) characterized by impaired fibrin alpha-chain cross-linking. Blood 2006; 108: 1919-1924.
• 20 Bowley SR, Merenbloom BK, Okumura N. et al. Polymerization-defective fibri-nogen variant gammaD364A binds knob ”A“ peptide mimic. Biochemistry 2008; 47: 8607-8613.
• 21 Di Stasio E, Nagaswami C, Weisel JW. et al. Cl- regulates the structure of the fibrin clot. Biophys J 1998; 75: 1973-1979.
• 22 Yamazumi K, Doolittle RF. The synthetic peptide Gly-Pro-Arg-Pro-amide limits the plasmic digestion of fibrinogen in the same fashion as calcium ion. Protein Sci 1992; 01: 1719-1720.
• 23 Nieuwenhuizen W, Vermond A, Nooijen WJ. et al. Calcium-binding properties of human fibrin(ogen) and degradation products. FEBS Lett 1979; 98: 257-259.
• 24 Lounes KC, Ping L, Gorkun OV. et al. Analysis of engineered fibrinogen variants suggests that an additional site mediates platelet aggregation and that ”B-b“ interactions have a role in protofibril formation. Biochemistry 2002; 41: 5291-5299.
• 25 Kostelansky MS, Lounes KC, Ping LF. et al. Probing the gamma2 calcium-binding site: studies with gammaD298,301A fibrinogen reveal changes in the gamma294-301 loop that alter the integrity of the ”a“ polymerization site. Biochemistry 2007; 46: 5114-5123.
• 26 Lewis SD, Shields PP, Shafer JA. Characterization of the kinetic pathway for liberation of fibrinopeptides during assembly of fibrin. J Biol Chem 1985; 260: 10192-10199.
• 27 Laudano AP, Doolittle RF. Influence of calcium ion on the binding of fibrin amino terminal peptides to fibrinogen. Science 1981; 212: 457-459.
• 28 Weisel JW, Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 1992; 63: 111-128.
• 29 Vu D, Neerman-Arbez M. Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins. J Thromb Haemost 2007; 05 (Suppl. 01) 125-131.
• 30 Koopman J, Haverkate F, Briet E. et al. A congenitally abnormal fibrinogen (Vliss-ingen) with a 6-base deletion in the gamma-chain gene, causing defective calcium binding and impaired fibrin polymerization. J Biol Chem 1991; 266: 13456-13461.
• 31 Terasawa F, Hogan KA, Kani S. et al. Fibrinogen Otsu I: A gammaAsn319,Asp320 deletion dysfibrinogen identified in an asymptomatic pregnant woman. Thromb Haemost 2003; 90: 757-758.